Inclusion Criteria:

- Male or female adults (age > / = 18 years)

- Diagnosed with one of the following types and stages of tumors: stage III or IV
breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage
III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large
B-cell lymphoma; multiple myeloma.

- Planned to receive primary prophylaxis with ZARZIO® at the first cycle of
chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis
with ZARZIO® irrespective of chemotherapy cycle.

- Treated with commercially available ZARZIO® per physician's best clinical judgment
and per current European ZARZIO® label.

- Female patients must be either post-menopausal for one year or surgically sterile or
using effective contraceptive methods such as barrier method with spermicide or an
intra-uterine device. Oral contraceptive use is allowed.

- Informed written consent to participate in the study by patients or their legal
guardian.

Exclusion Criteria:

- Patients with myeloid malignancies, with the exception of multiple myeloma.

- Sensitivity to ZARZIO® or any other CSF.

- Hypersensitivity to E. coli-derived proteins.

- Radiotherapy to ≥ 20% of total body bone.

- Infection within two weeks of starting current line of chemotherapy.

- Patients with several medical condition(s) that in view of the investigator prohibits
participation in the study.

- Patients with willfully negligent nonadherence to their cancer treatment.

- Use of any investigational agent in the 30 days prior to enrollment.

- Women of childbearing potential not using the contraception method(s) described
above.

- Women who are breastfeeding.